Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Open-Label, Multicenter, Single-Dose Study of the Pharmacokinetics of a Novel Extended-Release Oral Disintegrating Tablet Formulation (Adzenys XR-ODT) in Preschool-Aged Children

Trial Profile

A Phase 4, Open-Label, Multicenter, Single-Dose Study of the Pharmacokinetics of a Novel Extended-Release Oral Disintegrating Tablet Formulation (Adzenys XR-ODT) in Preschool-Aged Children

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2018 New trial record
    • 24 Oct 2018 According to a Neos Therapeutics media release, data will be presented at the at the 65th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top